Revolutionizing Biotechnology

Our gene therapy approach aims to correct genetic defects by delivering therapeutic genes to the affected cells, potentially curing a wide range of genetic diseases

Company located in Lithuania. The core team have more than 20 years of R&D experience

We are the holders of two technologies Peptide production and control growing of bacterial cellulose

Innovation point of view with the advantages of low-cost production gives wide abilities to take place in 1 trillion markets

Medical devices will be sold by the B2B model, using instruments of e-commerce to get a reputation and statistics

The products are under CE and FDA regulation of medical devices

We have more the 10 years of statistics data on efficiency company products IN-VITRO, IN-VIVA and volunteer tests. For CE have done clinical test

The European Commission supported company products for 2,6 M Euro. The company's generated positive cash flow, for research continues 

In our team, we have specialists to decrease risks: SMQ, ISO:13485

Then we collect enough clients and patients our exit strategy will be  acquisition by a larger company

We need financing for product development,  marketing, operational expenses, FDA certification